Introduction
Platelet-derived growth factor receptors (PDGFR) are cell surface tyrosine kinase receptors for members of the PDGF family (1) . PDGF/PDGFR signaling is reported to be involved in the regulation of various cell functions by activating three major signal transduction pathways including MAPK/Erk, PI3K, and PLC-γ (2) (3) (4) (5) .
Accumulating evidence suggests that PDGFR signaling plays an important role in the regulation of osteoblasts or mesenchymal stem cells (MSCs) . Recent experiments suggest that activation of PDGFR signaling by PDGF factor BB plays a positive role in bone formation (6, 7) . Fierro et al. (8) showed that inhibition of PDGFR activity by imatinib in vitro partially suppressed osteogenesis of MSCs. That said, some literature has suggested that PDGFR signaling suppresses osteoblast differentiation (9) (10) (11) . For example, Tokunaga et al. (12) found that knockout of the PDGFR-β gene in murine MSCs enhanced osteogenic differentiation. Clinically, long-term inhibition of PDGFR signaling by imatinib therapy has been reported to promote bone formation in patients with chronic myeloid leukemia (CML) (11, 13 Original Article activity, osteogenic marker gene expression, and matrix calcium deposition staining (14) . Some previous studies, however, have reported that PDGFR signaling inhibits osteogenesis. Furthermore, the mechanisms by which PDGFR signaling inhibits osteogenic differentiation remain unclear. Therefore, the present study examined the effect of PDGFR-β inhibition by Tyrphostin AG-1295, a potent PDGFR-β blocker (15) on matrix mineralization in MC3T3-E1 cells. Findings suggest that blocking of PDGFR signaling by Tyrphostin AG-1295 promotes osteoblast differentiation and mineralization and that activation of the Erk1/2 pathway might be involved in this process.
Materials and Methods

Chemicals and antibodies
PDGFR inhibitor AG-1295 was purchased from Calbiochem (San Diego, CA, USA). Alpha-modified minimum essential medium (α-MEM), Dulbecco's modified Eagle's medium (DMEM), and Fetal bovine serum (FBS) were purchased from Gibco (Rockville, MD, USA). β-Glycerophosphate, ascorbic acid, and dexamethasone were purchased from Sigma (St. Louis, MO, USA). Rabbit monoclonal antibodies for Erk1/2 and p-Erk1/2 were obtained from Cell Signaling Technology (Beverly, MA, USA).
Cells and osteoblast differentiation induction
The osteoblastic cell line MC3T3-E1 (subclone 14), which was established from normal mouse calvaria (16) , was purchased from the Cell Bank of the Type Culture Collection of the Chinese Academy of Sciences. MC3T3-E1 cells were cultured in α-MEM supplemented with 10% FBS and 1% penicillinstreptomycin. To stimulate mineralization, MC3T3-E1 cells at 1 × 10 4 cells/well were first cultured in 24 or 6-well plates to 80% to 90% confluence, and then cells were placed in osteogenic media (DMEM with 10% FBS, 1% penicillin-streptomycin, 10 mmol/L β-glycerophosphate, 50 μg/mL ascorbic acid, and 10 nmol/L dexamethasone) in the absence (the positive control group) or presence of AG-1295 (1, 10, and 20 μmol/L) for the times indicated. The negative control group was placed in basic medium (DMEM with 10% FBS, 1% penicillin-streptomycin) alone.
ALP activity
MC3T3-E1 cells were cultured in 24-well (1 × 10 4 cells/well) plates during osteogenic induction as described above. After treatment, cell lysates were prepared with 100 μL assay buffer containing 25 mM Tris-HCl (pH 7.4) and 0.5% Triton X-100. Fifty μL of each sample was mixed with 100 μL p-nitrophenyl phosphate (PNPP) substrate (Sigma) and cells were incubated at 37°C for 30 min. The absorbance of the colored product was detected at 405 nm. Cellular ALP activity was normalized to total protein content using the bicin-choninic acid (BCA) method.
Analysis of mineralization
After osteogenic induction, mineral deposition was assessed by staining with Alizarin-Red on days 21, 25, and 30. The cells were fixed in formalin for 20 min at room temperature and washed with distilled water. A 2% Alizarin Red solution was added to the fixed cells and cells were incubated for 10-20 min. Culture plates were rinsing with distilled water and then imaged.
Quantitative real-time polymerase chain reaction (RT-qPCR)
Total RNA was prepared at the indicated time points using Total RNA Kit I (Omega, Bio-Tek, Norcross, GA, USA) in accordance with the manufacturer's instructions. Complementary DNA (cDNA) was synthesized using ReverTra Ace qPCR RT Kit (Toyobo). Real-time PCR was performed as usual with SYBR Green mix (Toyobo, Osaka, Japan) and a Lightcycler 480 (Roche Applied Science, Mannheim, Germany). Gene-specific primer sequences are listed in Table  1 . Gene expression was normalized with the acidic ribosomal phosphoprotein P0 (36B4) of the mouse housekeeping gene (17) . Cycling conditions were 94°C , 15 min, followed by 40 cycles of 94°C, 15 sec; 57°C, 20 sec; and 72°C, 10 sec.
Western blotting
After treatment, cells were lysed in lysis buffer (50 mmol/L Tris-HCl, pH 7.4, 150 mmol/L NaCl, 1 mmol/L ethylenediaminetetraacetic acid, 0.25% Nadeoxycholate, 1% NP-40, 1 mmol/L phenylmethanesulfonylfluoride, 1 mmol/L sodium orthovanadate, 1 μg/mL leupeptin, 1 μg/mL aprotinin, and 1 μg/mL pepstatin). Equivalent amounts (25 μg) of protein were separated on 12% sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) gels and subsequently transferred to Hybond-enhanced chemiluminescence (ECL) nitrocellulose membranes. Membranes were probed with antibodies against total Erk1/2, phospho-Erk1/2, and Actin. Protein bands were observed using ECL and specific bands were detected with X-film.
Statistical analysis
Statistically significant differences between groups were determined using an unpaired Student's t-test. Statistical significance was defined as p < 0.05. nodule mineralization in a concentration-dependent manner. Cells treated with 10 μmol/L and 20 μmol/L AG-1295 had obvious mineralized nodules on day 21, while MC3T3-E1 cells cultured in osteogenic media had obvious mineralized nodules prior to day 30 (Figure 2 ).
Effect of AG-1295 on the expression of osteoblastspecific marker genes in MC3T3-E1 cells during osteoblast induction
Real-time PCR results for osteogenic marker genes collagen type I (Col1A), runt-related transcription factor 2 (Runx2), osterix (Osx), tissue-nonspecific alkaline phosphatase (Tnap), osteocalcin (Ocn), and progressive ankylosis (AnK) are shown in Figure 3 . According to the measured level of ALP activity and Alizarin Red S staining, blocking PDGFR-β with AG-1295 could elevate the mRNA expression of most of the osteogenic markers investigated. After AG-1295 treatment, significantly up-regulated mRNA levels of Col1A, Runx2, Osx, Tnap, and Ocn were identified on days 9 and 14. However, AG-1295 down-regulated the expression of Ank.
Effect of PDGF-β inhibition by AG-1295 on the Erk1/2 pathway in MC3T3-E1 cells
To evaluate whether the Erk1/2 pathway is involved in the regulation of AG-1295 as part of mineralization in
Results
PDGFR-β kinase inhibitor Tyrphostin AG1295 increased ALP activity during the early stages of osteoblast differentiation in MC3T3-E1 cells
ALP activity was assessed as an early indicator of osteoblastic lineage to study the effect of AG-1295 on the osteogenic differentiation of MC3T3-E1 cells. ALP activity was determined on days 3, 6, 9, and 14 with osteogenic induction in the presence or absence of AG-1295 (1, 10, and 20 μmol/L). Figure 1 shows the ALP activity of MC3T3-E1 cells under different conditions. ALP activity in all groups of MC3T3-E1 cells peaked on day 9 and decreased on day 14, which is consistent with the results of previous studies. ALP activity increased significantly by 20 μmol/L AG-1295 on days 3, 6, and 9 (p < 0.05). However, there were no significant differences in ALP activity in the groups on day 14. This indicates that AG-1295 increased ALP activity during the early stages of osteoblast differentiation in MC3T3-E1 cells.
PDGFR-β kinase inhibitor Tyrphostin AG-1295 enhanced matrix mineralization in MC3T3-E1 cells
MC3T3-E1 cells were stained with Alizarin Red to detect nodule mineralization on days 21, 25, and 30. As shown in Figure 2 , AG-1295 markedly enhanced MC3T3-E1, the expression of total and phosphorylated Erk1/2 protein was detected with Western blotting. As shown in Figure 4 , a marked level of phosphorylated Erk1/2 protein was detected on 10 day of osteogenic induction, while no significant changes in the level of total Erk1/2 were noted. Furthermore, the phosphorylation activation of Erk1/2 was significantly suppressed by 20 μmol/L Tyrphostin AG-1295 in MC3T3-E1 cells cultured in osteogenic media on day 10.
Discussion
The current study demonstrated that blocking PDGFR signaling with Tyrphostin AG-1295 significantly promoted osteoblast mineralization. AG-1295 increased ALP activity in the early stages of osteoblast differentiation in MC3T3-E1 cells and enhanced matrix mineralization in the later stages of osteoblast differentiation. Like osteoblast phenotype induction, AG-1295 also increased the expression of most osteogenic markers. These findings suggest that PDGFR signaling suppresses osteoblast differentiation. The current findings differ from those of a previous study by Kumar et al., in which another PDGFR inhibitor, AG-1296, failed to affect the osteogenic differentiation of human mesenchymal stem cells (MSCs). Differences may have arisen because of the different cell lines and PDGFR inhibitors used. Human MSCs give rise to osteoblastic lineages when cultured in specific differentiation media. Both MC3T3-E1 and human MSCs are commonly used in studies of osteogenic differentiation. They also have a similar mineralization process. Differences in results may be due primarily to different PDGFR inhibitors. AG-1296 has been found to inhibit PDGFR-α longer and greater than AG-1295, while AG-1295 is a specific inhibitor of PDGFR-β (18, 19) . Nemoto et al. (20) indicated that during formation of mineralized nodules PDGFR-β remained slightly elevated while PDGFR-α remained slightly depressed. Therefore, the current findings also suggest that PDGFR-β rather than PDGFR-α signaling is involved in the regulation of osteoblast differentiation.
The detailed mechanism for regulation of mineralization by PDGFR signaling is not clear at present. Several previous studies have shown that the Erk pathway, a downstream effector of PDGFR signaling, is essentially involved in regulation of matrix mineralization. Higuchi et al. (21) demonstrated that Erk inhibitor PD98059 promoted osteoblastic differentiation induced by BMP-2 in C2C12 pluripotent mesenchymal cells. Chaudhary and Avioli reported that Erk activation by PDGF factor BB or fibroblast growth factor-2 suppressed type I collagen expression in MC3T3-E1 cells (22) . These findings suggest that the Erk pathway is a negative regulator of osteoblastic differentiation. To explore the possible role AG1295 plays in osteogenesis, its effect on the Erk1/2 pathway was investigated in MC3T3-E1 cells. As expected, the phosphorylation activation of Erk1/2 was significantly suppressed by 20 μmol/L Tyrphostin AG-1295 in MC3T3-E1 cells at day 10, which suggests that AG-1295 might promote osteoblast differentiation by suppressing the activation of Erk1/2, a downstream factor of the PDGFR pathway.
In summary, the present study has demonstrated that inhibition of PDGFR signaling by Tyrphostin AG-1295 significantly promoted osteogenesis via the Erk1/2 pathway. Findings suggest that PDGFR-β signaling might play an important role in osteoblast differentiation. 
